NASDAQ · Biotechnology

SVRA (SVRA) Stock

$5.35 -1.47% NASDAQ: SVRA Healthcare

Valuation

MetricValue
Price$5.35
Market Cap$1.10B
P/E Ratio-18.45
P/B Ratio7.82
P/S Ratio0.00
EPS (TTM)$-0.33
52-Week High$7.00
52-Week Low$1.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-79.95%
ROA-40.53%
ROCE-61.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.17
Current Ratio12.10

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-41.0M$-39.0M$-60.0M$-103.0M$-124.0M
Net Profit$-43.0M$-38.0M$-55.0M$-96.0M$-119.0M
EPS$-0.32$-0.25$-0.33$-0.48$-0.53
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$177.0M$140.0M$178.0M$213.0M$253.0M
Total Liabilities$32.0M$32.0M$37.0M$41.0M$50.0M
Cash$34.0M$52.0M$27.0M$15.0M$33.0M
Borrowings$26.0M$26.0M$26.0M$27.0M$30.0M

Latest News

Here's Why You Should Add Savara Stock to Your Portfolio Now Zacks · Jul 22, 2026 Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors GlobeNewswire · Jun 30, 2026 What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline Motley Fool · Jun 27, 2026 Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing MT Newswires · Jun 23, 2026 Savara Announces New Employment Inducement Grant Business Wire · Jun 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-40.0M$-35.0M$-51.0M$-89.0M$-101.0M
Investing Cash Flow$-70.0M$53.0M$-57.0M$-40.0M$-18.0M
Financing Cash Flow$-1.0M$0$-1.0M$-1.0M$-5.0M
Net Cash Flow$11.0M$18.0M$-26.0M$-11.0M$18.0M
Free Cash Flow$-40.0M$-35.0M$-51.0M$-89.0M$-101.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA-8.71
FCF Yield-9.62%
Quick Ratio13.47
Interest Coverage—
Return 1Y130.92%
Return 3Y67.64%
Return 5Y334.35%

Ownership

Insiders Held2.58%
Institutions Held104.37%
Institutions Float Held107.13%
Institutional HolderSharesReport Date
NEA Management Company, LLC24,471,2642026-03-31
Bain Capital Life Sciences Investors, LLC17,600,6212026-03-31
Venrock Adviser, LLC13,740,3752026-03-31
Deerfield Management Company, L.P13,569,0002026-03-31
TCG Crossover Management, LLC12,362,2052026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
GERN $1.34 -4.29% 23.17 $859.64M 0.00%
GHRS $29.10 -0.06% -10.34 $2.00B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%

About SVRA

SVRA is led by CEO Matthew Pauls, employs 59 people, headquartered in US, publicly traded since 2017.

SVRA stock trades at $5.35 with a market capitalization of $1.10B. The stock is valued at a price-to-earnings (P/E) ratio of -18.45, price-to-book of 7.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.98 and $7.00, and currently trades 23.6% below its 52-week high.

On profitability, SVRA generates a return on equity (ROE) of -79.95%, return on capital employed of -61.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides